- Home
- BMEZ vs MGTX Comparison
BMEZ vs MGTX Comparison
Compare BMEZ & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMEZ | MGTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.6M | 909.1M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BMEZ | MGTX |
|---|---|---|
| Price | $15.27 | $12.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.57 |
| AVG Volume (30 Days) | 195.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $13.67 | $6.62 |
| 52 Week High | $15.80 | $15.35 |
Technical Indicators
Market Signals| Indicator | BMEZ | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 54.21 |
| Support Level | $15.01 | $7.21 |
| Resistance Level | $15.76 | $15.35 |
| Average True Range (ATR) | 0.21 | 0.94 |
| MACD | -0.06 | -0.21 |
| Stochastic Oscillator | 32.88 | 19.60 |
Price Performance
Historical ComparisonAbout BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Term Trust is a closed-end fund focused on the healthcare and health sciences sector. Its investment objectives are to provide total return and income through long-term capital appreciation.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.